In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Armkel

This article was originally published in The Rose Sheet

Executive Summary

Depilatory and skin care sales up 3% to $27.5 mil. in second quarter, firm reports in 10Q filed with the Securities and Exchange Commission Aug. 8. Increase is led by 14% gain in Nair sales for the period (1"The Rose Sheet" Aug. 12, 2002, p. 5). Sales for smallest Armkel product category, oral care (Pearl Drops), soared 21% to $8.9 mil. for quarter. Results for the 50/50 Church and Dwight/Kelso & Co. partnership formed to purchase most Carter-Wallace consumer products are compared to C-W for previous year. Armkel total net sales advanced 1.8% to $115.9 mil. in Q2...

You may also be interested in...



Nair Retail Sales Rise 14% In Q2 On Line Extensions

Retail sales for Nair depilatories advanced 14% in the second quarter with the addition of new wax products, Church & Dwight reported Aug. 5

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 

NGM’s Pan-FGF Receptor Approach In NASH Shows Benefits And Drawbacks

NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.

UsernamePublicRestriction

Register

RS010530

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel